523results about "Pill delivery" patented technology

The invention relates to a pharmaceutical composition comprising a fixed dose combination of (a) Netupitant or salt or hydrate thereof, and (b) Palonosetron or salt or hydrate thereof, in a single pharmaceutical unit. The invention further relates to a method of preparing a pharmaceutical composition in the form of a tablet, the method comprising: (i) wet granulating a dry mixture comprising Netupitant or a salt or hydrate thereof, filler, a binder, a disintegrant, and optionally a surfactant and / or a lubricant, with a solution comprising Palonosetron or a salt or hydrate thereof, and optionally a surfactant and / or a binder, to produce granules, (ii) blending the granules with a lubricant, a disintegrant and a glidant, and optionally a filler, and (iii) compressing of the lubricated granules to produce a tablet. The invention further relates to the pharmaceutical composition for use in the treatment and / or prevention of nausea and / or vomiting, preferably in the treatment and / or prevention of acute or delayed nausea and vomiting associated with chemotherapy, such as highly or moderately emetogenic cancer chemotherapy, for example cisplatin cancer chemotherapy.

The present invention relates to mini-tablets in capsule formulation comprising lisdexamfetamine dimesylate and at least one stabilizer. Furthermore, the invention discloses a process which is simple, rapid, cost effective, time-saving and industrially convenient process and is created to eliminate the disadvantages of active agent.

In the specification of the present application, an oral immediate-release formulation of bexagliflozin for administration to a companion animal is provided.

The present invention discloses compositions and methods comprising enriched bisdemethoxycurcumin (BDMC) present at 20% by weight or greater for use in inhibiting receptor for advanced glycation end products (RAGE) expression in a subject with a chronic inflammatory condition. The composition further comprises beta-amyrin palmitate (BAP). The present invention also discloses the use of the composition in managing a chronic inflammatory condition in a subject.

The application discloses a kind of bumetanide tablets, raw materials include bumetanide 1 according to mass ratio;Corn starch 81~85;Lactose 50~54;Agar 0.1~0.3;Povidone K304~6;Polysorbate 80, 0.1~0.2;Silicon dioxide 3~4.5;Talcum powder 2~3.3;Magnesium stearate 0.3~0.7.Its preparation method includes the following steps: pretreatment, premixing, granulation, wet granulation, drying, dry granulation, total mixing, tabletting and packaging.The application introduces the synergistic system of trace agar and polysorbate 80 in the prescription.Agar, as a natural hydrophilic colloid, can form a hydrophilic network structure during the granulation process, and synergistically act with polysorbate 80, greatly improving the wettability and dispersibility of the slurry to ultrafine bumetanide, preventing drug agglomeration, so that the drug can be more evenly distributed in the granules during the subsequent drying and tabletting process.

The present invention discloses an antitumor pharmaceutical composition based on immune checkpoint blockade and its application, which comprises paroxetine hydrochloride and a T cell enhancer, which is at least one of vitamin E and thymosin. Through a series of in vitro and in vivo experiments, the present invention has first discovered that cannabidiol and paroxetine hydrochloride can effectively reduce the expression of PD-L1 on the surface of tumor cells, block the PD-1 / PD-L1 signaling pathway, and enhance the tumor cell killing effect of T cells. Based on this, the addition of a T cell enhancer can further increase the number and activity of T cells, significantly enhancing the killing ability of T cells after immunosuppression is released, thereby significantly enhancing the antitumor effect of the drug. The components of the pharmaceutical composition of the present invention, cannabidiol, paroxetine hydrochloride, vitamin E, and thymosin, exert a synergistic effect, improving the antitumor effect.

Methods of treatment of addiction and / or dependence, methods of promoting cessation of various addictions, such as smoking and / or vaping, and methods of promoting a reduction in various addictions, such as smoking and / or vaping, uses of cytisine as an addiction cessation treatment, and dosage regimens for the foregoing are provided.

The present application provides a traditional Chinese medicine composition, a preparation method and application thereof. Specifically, the traditional Chinese medicine composition comprises an active ingredient and an auxiliary material, wherein the active ingredient is prepared from the following raw materials: pollen typhae, salvia miltiorrhiza, rehmannia glutinosa, eclipta prostrata, chrysanthemum, scutellaria baicalensis, semen cassiae, plantago, herba lycopi, ligustrum lucidum, prunella vulgaris, gentiana, curcuma, equisetum, red peony root, cortex moutan, hawthorn, angelica sinensis, chuanxiong; wherein the auxiliary material can comprise dextrin; and the weight of dextrin is less than or equal to 1% based on the total weight of the active ingredient. The traditional Chinese medicine composition and the preparation method thereof can meet the requirements of the pharmaceutical process, have better fluidity, and are more conducive to the preparation of subsequent preparations.

Ganoderma lucidum spore oil and its use in preparing anti-cancer-related fatigue medicine. The Ganoderma lucidum spore oil has a triglyceride content of more than 90% and no Ganoderma lucidum triterpenoid compounds are detected. The Ganoderma lucidum spore oil is obtained by supercritical carbon dioxide extraction, eluting with a mixture of petroleum ether and ethyl acetate through a silica gel column, concentrating under reduced pressure, and drying in vacuum. The Ganoderma lucidum spore oil is found to significantly improve fatigue caused by cancer and has good safety, and therefore can be applied to preparing anti-cancer-related fatigue medicine.

There are disclosed psychedelic and entactogen compounds, the use of such compounds in the treatment of diseases associated with a serotonin 5-HT2 receptor, pharmaceutical compositions such as tablet compositions and kits containing the compounds, methods of delivering the compounds in a mist via inhalation, and methods of treating diseases or disorders associated with a serotonin 5-HT2 receptor, such as central nervous system (CNS) disorders or psychological disorders with the compounds of the invention.

Methods for treating injuries to the central nervous system with a cilia activator are provided. The injury may be a traumatic brain injury (TBI). Related pharmaceutical compositions are provided.

Disclosed are compositions for the oral or nasal cavity. The compositions comprise a biologically active agent, a matrix forming agent comprising beta-glucan, and a bulking agent. The compositions can also comprise additional excipients, such as antioxidants, preservatives, taste or flavor enhancers, pH adjusting agents, plasticizers, and sweeteners. Also disclosed are methods of manufacturing the compositions.

The present invention relates to pharmaceutical compositions, specifically bilayer tablet formulations containing mirabegron and solifenacin succinate. The invention particularly addresses improvements in in-vitro release of solifenacin succinate in immediate release layer by improved manufacturing processes.

Described herein are methods of treating non-metastatic castration-resistant prostate cancer in a subject with severe hepatic impairment with an androgen receptor inhibitor, including but not limited to 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide.

The present invention relates to a syrup containing alectinib or a salt thereof. The present invention provides a syrup containing alectinib or a salt thereof, which is a poorly water soluble agent, and having improved fluidity and / or palatability. The syrup of the present invention has a plasma concentration profile equivalent to or greater than, or is biologically equivalent to, a capsule containing the same amount of alectinib or a salt thereof as the syrup, or has an enhanced oral bioavailability compared to a capsule containing the same amount of alectinib or a salt thereof as the syrup.

The application belongs to the technical field of pharmaceutical preparations, and discloses a trimetazidine hydrochloride tablet and a preparation process thereof.The trimetazidine hydrochloride tablet is composed of trimetazidine hydrochloride, lactose, microcrystalline cellulose, sodium crosslinked carboxymethyl cellulose and other auxiliary materials, and specific auxiliary components are added simultaneously.The preparation process comprises the following steps in sequence: pretreatment of core components, inclusion and dispersion, mixing of soft materials, granulation, drying, total mixing and tablet pressing, and the solubility and dispersibility of the drug are effectively improved.The trimetazidine hydrochloride tablet can realize rapid and sufficient release of the drug, has excellent content uniformity, provides precise and stable dose guarantee for clinical medication, and meets the clinical treatment requirements.

This invention relates to the field of health food and pharmaceutical preparation technology, specifically to a method for preparing ginsenoside freeze-dried flash-release tablets. These ginsenoside freeze-dried flash-release tablets are made from the following raw materials in the indicated weight ratios: 3-5 parts ginseng extract, 8-12 parts matrix support agent, 1.5-2.5 parts binder, and 0.3-0.5 parts prebiotics. The method includes the following steps: S1, ingredient dissolution; S2, high-speed emulsification; S3, vacuum degassing; S4, quantitative filling; S5, ultra-low temperature quick-freezing; S6, programmed freeze-drying; and S7, aluminum-aluminum sealed packaging. This invention has the advantages of convenient administration, rapid absorption, pure formulation, good stability, and excellent taste.

The application provides an oral instant tablet containing Morinda citrifolia oil, which comprises the following components in parts by mass: Morinda citrifolia oil microemulsion 10 parts, carrier 30-40 parts, coating material 2-4 parts, and disintegrating agent 2-5 parts. The coating material is selected from Aeroperl and / or Sylysia; the carrier is selected from one or more of microcrystalline cellulose MCC PH101, microcrystalline cellulose MCC PH102, starch and lactose; and the disintegrating agent is selected from carboxymethyl starch sodium and / or low-substituted hydroxypropyl cellulose. The microemulsification technology is used to wrap the essential oil to reduce the volatilization of the essential oil; the microemulsion is made into a tablet to cover the acidity, increase the compliance of the public, and realize the form change of the Morinda citrifolia oil microemulsion from liquid to solid. The application studies and prepares the oral instant tablet containing Morinda citrifolia oil, which not only solves the inherent defects of traditional dosage forms, but also provides a more convenient taking mode compared with common tablets.

The present invention relates to pharmaceutical compositions containing a solid dispersion of N- [2,4-B is( 1, 1 -dimethy lethyl)-5 -hydroxypheny 1] - 1,4-dihydro-4-oxoquinoline-3 - carboxamide including formulations of the solid dispersions into powders, granules and mini- tablets, methods for manufacturing and processing the powders, granules and mini-tablets, and methods for treating cystic fibrosis employing the pharmaceutical composition.

This specification describes a formulation comprising a homogeneous suspension of a biopolymer(s) for drug delivery of an active molecule. In an embodiment, the biopolymer is selected from chitin, chitosan, cellulose, hemicellulose, lignin, amylose, actin, fibrin, collagen, silk, fibroin, keratin, wool, alginic acid, and mixtures thereof. In an embodiment, the biopolymer is mechanically treated with an API under high shear conditions and / or high mechanical energy. The formulation can find particular use in drug delivery systems that involve the transport and release of compounds or molecules for purposes such as pharmaceuticals, drug substances, cosmetics, and the like.

Disclosed is a target for use in a toilet or urinal, and a toilet or urinal having the article. Also disclosed is a method for entertaining users of a toilet or urinal, in which the article is applied, and to a method for manufacturing the article and a computer readable medium, having instructions for 3D printing the article.

One purpose of the present invention is to treat or prevent chronic heart failure. Provided are: a pharmaceutical composition for treating or preventing chronic heart failure, said composition comprising a compound that inhibits SGLT1 or a pharmaceutically acceptable salt thereof; and a treatment or prevention method for chronic heart failure, said method being characterized by comprising administering a compound that inhibits SGLT1 or a pharmaceutically acceptable salt thereof.

Provided is a technique for suppressing discoloration during production of a solid composition containing a tranexamic acid, and improving the uniformity of the appearance. The solid composition contains component (A) selected from at least one of tranexamic acid and a salt thereof, and component (B) isomalt.

This invention relates to methods for treating endometriosis and providing effective contraception. Specifically, it relates to drospirenone in methods for treating endometriosis, endometriosis-associated pelvic pain (EAPP), and / or dysmenorrhea, the method comprising administering drospirenone in a biphasic regimen. The invention also relates to the use of drospirenone administered in such a biphasic regimen as a contraceptive and for inducing amenorrhea, and to pharmaceutical compositions and devices comprising drospirenone administered in such a biphasic regimen.

The application discloses a ginseng stem and leaf composition based on fine extraction, a tablet and a production process, belongs to the technical field of natural medicine preparation, and aims to solve the problems of low utilization rate of ginseng stem and leaf components, complex rare saponin conversion process and poor bioavailability of products in the prior art. The core process comprises the following steps: fine separation of hydrophilic ginseng flavone / ginseng polysaccharide component A and saponin precursor component by adopting enzyme-assisted extraction combined with double-membrane filtration and fractional elution; solid phase thermal conversion of the saponin precursor component into lipophilic conversion component B rich in rare saponins Rg5, Rk1 and Rh4 by using a solid acid catalyst; and further preparation of the lipophilic conversion component B into a solid self-microemulsifying carrier, and compression of the hydrophilic ginseng flavone / ginseng polysaccharide component into a double-layer tablet.

An antihistamine compound having the structure of formula (I), a pharmaceutically acceptable salt thereof, a method for preparing the same, and use of the antihistamine compound having the structure of formula (I) and a pharmaceutically acceptable salt thereof in the treatment of diseases such as seasonal / perennial allergic rhinitis, allergic conjunctivitis, and urticaria. JPEG2025519827000061.jpg85170

The application discloses a preparation method of finasteride tablets, and relates to the technical field of medicine preparation. The method comprises the following steps: after a surfactant is prepared into an aqueous solution, a first prescription amount of a binder is added to form a binder suspension slurry; finasteride, a filler, a first prescription amount of a disintegrating agent and a second prescription amount of the binder are premixed to obtain a premix; the binder suspension slurry is added into the premix to perform wet granulation to prepare wet granules; after the wet granules are dried and granulated, the wet granules are mixed with a second prescription amount of the disintegrating agent and a lubricant, and then tabletting is performed, so that the finasteride tablets are obtained. On the basis of ensuring that the tablets can be rapidly released, the method realizes that the hard tablets with appropriate hardness and stable properties can be obtained under a lower main tabletting pressure. In addition, the method uses non-organic solvents for granulation, so that the stability, safety and industrial production efficiency of the final product are all remarkably improved under the premise that no non-standard prescription auxiliary materials are additionally added.

The application discloses a kind of medicine and food homologous plant composition and its tabletting preparation method.The composition is composed of hawthorn powder, medlar powder, natto powder and licorice powder according to specific weight parts, wherein the natto powder is treated by vacuum low-temperature drying, the medlar powder is treated by vacuum freeze drying and the medlar polysaccharide is embedded, and the licorice powder is obtained by β-cyclodextrin inclusion treatment of licorice extract containing glycyrrhizic acid.The particle size distribution, moisture content and bulk density of each raw material powder are matched and controlled, so that the obtained composition has good fluidity and mixing uniformity, and can be prepared into tablets by direct compression.The composition improves the hygroscopicity and tabletting adaptability while maintaining the stability of the main active ingredients, and the prepared tablets have stable mechanical properties and storage stability, suitable for industrial production.

Methods and compositions for use in improving heart function and health are disclosed. The methods and compositions are based on urolithin.